Acute metabolic effects of cannabinoid receptor modulators during sequential hyperglycemic, euglycemic-hyperinsulinemic clamps in healthy individuals
In healthy men, acute administration of the cannabinoid receptor agonist nabilone enhanced peripheral insulin sensitivity while reducing fasting endocannabinoid levels, whereas the CB1 receptor antagonist CP-945,598 diminished insulin sensitivity in a dose-dependent manner. Neither agent acutely altered glucose-stimulated insulin secretion during hyperglycemic clamps, suggesting that cannabinoid modulation primarily impacts peripheral insulin action rather than beta-cell insulin release in humans.
A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome
This pilot study indicates that medicinal cannabis may be a feasible treatment option for adolescents with Tourette Syndrome, warranting further investigation in a fully powered trial.
Adverse events caused by cannabinoids in middle aged and older adults for all indications: a meta-analysis of incidence rate difference
Clinicians should be cautious when prescribing cannabinoid-based medicines to older adults due to the limited data on adverse events. Monitoring for potential adverse effects is essential.
Acute Effects of Cannabis on Alcohol Craving and Consumption: A Randomized Controlled Crossover Trial
Clinicians should be aware of the complex relationship between cannabis use and alcohol consumption, as THC may have varying effects on alcohol craving and consumption.
A Synthetic Form of Cannabinoid Does Not Decrease Opioid Use After Total Knee Arthroplasty: A Prospective, Randomized, Triple-Blind, Placebo-Controlled Study
In this prospective, triple-blind, placebo-controlled trial, oral dronabinol (2.5 mg twice daily) failed to reduce opioid consumption or improve secondary pain and sleep outcomes following primary total knee arthroplasty. These findings suggest that standard low-dose synthetic THC offers no significant adjunctive benefit for acute postoperative pain management in cannabis-naïve surgical patients.
Oral Cannabis Extract for Chemotherapy-Induced Nausea and Vomiting: A Randomized, Placebo-Controlled Phase II/III Trial
A randomised trial in adults who were still being sick during chemotherapy despite already taking the standard anti-sickness medicines.
Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome
A crossover trial in which 22 people with severe Tourette syndrome took both an oral THC/CBD oil and a placebo, six weeks each, without knowing which was which.
Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol
Researchers followed adults with advanced cancer receiving palliative care to see if a daily plant oil containing equal parts of active cannabis compounds could lower their overall distress. Participants took either the cannabis oil or an identical-looking inactive oil, starting with low amounts and adjusting upwards over four weeks while keeping their usual medical care.
Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson’s Disease: A Randomized Trial
A short randomised trial of a high-CBD, low-THC oral extract in 61 people with Parkinson's disease, a group who use cannabis often despite thin evidence.
“Does cannabis help with nausea during chemotherapy?”
For nausea that persists despite standard anti-sickness medicine, there is real evidence it helps. In a randomised trial, adding a THC:CBD capsule to the usual regimen raised the proportion of people who got through five days...
